清开灵注射液体外抑制HIV-1作用  

Inhibitory effect of Qingkailing injection on HIV-1 in vitro

作　　者：赵令斋[1,2] 曾耀英[1] 黄秀艳[1] 曾祥凤[1] 林长乐[1] 唐先高[1] 

机构地区：[1]暨南大学生命科学技术学院组织移植与免疫研究中心,广东广州510632 [2]广州市第八人民医院传染病研究所,广东广州510060

出　　处：《暨南大学学报（自然科学与医学版）》2009年第2期176-179,共4页Journal of Jinan University(Natural Science & Medicine Edition)

基　　金：“973”国家重点基础研究项目(2004CB720100,2006CB504201);广州市科技计划项目(2006Z1-E0091)

摘　　要：目的:研究清开灵注射液(QKL)体外抑制HIV-1的作用。方法:用MTT比色法检测QKL对H9/HIV-1ⅢB细胞(慢性感染HIV-1ⅢB的H9细胞)和MT-2细胞的毒性;采用荧光染料Calcein-AM标记的H9/HIV-1ⅢB细胞和系列稀释的QKL作用后,与MT-2细胞混合培养,2 h后在荧光下计数融合细胞数目,评价QKL对两种细胞早期融合的影响;用MTT法检测QKL对HIV-1ⅢB急性感染的MT-2细胞的保护作用;用HIVp24抗原试剂盒检测HIV-1ⅢB感染的MT-2细胞的培养上清p24抗原的含量,分析QKL对HIV-1复制的影响。结果:QKL对H9/HIV-1ⅢB细胞和MT-2细胞的CC50分别为1/50.76和1/36.97;抑制H9/HIV-1ⅢB细胞和MT-2细胞早期融合作用的EC50=1/235.29,SI=6.36;对HIV-1ⅢB感染的MT-2细胞保护作用的EC50=1/144.93,SI=3.92;抑制p24抗原产生作用的EC50=1/175.44,SI=4.75。结论:QKL体外有抗HIV-1活性,作用机制可能是多靶点的,可抑制病毒进入细胞和胞内复制。Aim： To investigate the inhibitory effect of Qingkailling（QKL） on HIV-1 in vitro. Methods： The cytotoxicity of QKL was detected by MTT assay. H9/HIV-1 ⅢB cells labeled calcein-AM were treated with serially diluted QKL, and then co-cultured with MT-2 cells. After 2 hours, the cell fusion was observed with a fluorescencmicroscope. The protective effect of QKL on MT-2 cells infected by HIV- 1 ⅢB was detected by MTT. Viral replication was analyzed by measuring the level of p24 antigen in culture supernatants by p24 kit. Results： QKL was toxical to H9/HIV-1 ⅢB cells and MT-2 cells. The CC50 was 1/50.76 and 1/36.97 respectively. The EC50 of QKL against early Hg/HIV-1 ⅢB ceils and MT-2 ceils fusion was 1/235.29 with a selective index of 6.36. QKL could protect MT-2 ceils direct infected by HIV- 1 ⅢB from death. The ECso was 1/144.93 with SI 3.92. The EC50 of QKL against P24 antigen production was 1/175.44 with SI of 4.75. Conclusion： QKL has inhibitory effect on HIV-1 in vitro and it reacted through at least two clarified antiviral mechamisms. QKL inhibited not only entry of HIV-1 into cell but also the replication.

关 键 词：清开灵注射液 人类免疫缺陷病毒Ⅰ型(HIV-1) 细胞融合 抑制作用 

分 类 号：R373.3[医药卫生—病原生物学]